February 8, 2017 / 3:44 PM / 8 months ago

BRIEF-Bayer late-stage rivaroxaban trial meets primary endpoint early

Feb 8 (Reuters) - Bayer AG

* Says Phase III compass study with rivaroxaban in patients with coronary or peripheral artery disease shows overwhelming efficacy and meets primary endpoint early

* Says Bayer, Janssen and Population Health Research Institute (PHRI) will offer rivaroxaban to study participants in an open-label extension trial

* Says a complete data analysis from this study is expected to be presented at an upcoming medical meeting in 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below